Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

219 Clinical Updates found
MSK Head and Neck Cancer: Thyroid Cancer Research Update Add to Default shortcuts Primary tabs View Edit Outline Delete Revisions Dynamic Yield Usage Convert Bundle Clone MSK
MSK Head and Neck Cancer: Thyroid Cancer Research Update
Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.
Three Decades in the Making: Advancing Rectal MRI at MSK
Three Decades in the Making: Advancing Rectal MRI at MSK
In this Q&A we discuss MSK’s pioneering work in rectal MRI, how it differs from endorectal ultrasound (ERUS), its role in groundbreaking clinical trials for patients with rectal cancer, why expertise matters, and new frontiers for future improvements to rectal MRI.
Neoadjuvant and Adjuvant Pembrolizumab with Standard-of-Care Significantly Improves Event-Free Survival in Head and Neck Cancer
Neoadjuvant and Adjuvant Pembrolizumab with Standard-of-Care Significantly Improves Event-Free Survival in Head and Neck Cancer
Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.
Doctor and patient shaking hands
ASCO 2025 Research Roundup: MSK Presents Practice-Changing Advances in Cancer Research
MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.
Physician looking at breast imaging
ASCO 2025 News: Groundbreaking Survival Advances for Patients with ER+/HER2- Advanced Breast Cancer
Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.
Radiation therapy during surgery with brachytherapy
Brachytherapy for Brain Metastases
As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease.
Vivian Strong, MD
Vivian Strong, MD, Gives a U.S. Perspective on Gastric Cancer at the 16th International Gastric Cancer Congress
Memorial Sloan Kettering’s Vivian Strong, MD, FACS, addressed peers from around the world in May 2025 at the 16th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global Fight for Innovation, the U.S. Perspective,” as the meeting’s Jin Pok Kim Lecturer.
AACR 2025 Research Roundup: Highlights of MSK’s Advances in Oncology Research
AACR 2025 Research Roundup: Highlights of MSK’s Advances in Oncology Research
Memorial Sloan Kettering Cancer Center (MSK) experts presented their latest advances in oncology research at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25 to 30 in Chicago.
Secondary Rectal Cancer After Radiotherapy for Prostate Cancer Differs From Primary Rectal Cancer
Secondary Rectal Cancer After Radiotherapy for Prostate Cancer Differs From Primary Rectal Cancer
Patients with secondary rectal cancer after radiotherapy for prostate cancer have shorter survival compared with matched treatment-naïve patients. However, a new study by investigators at MSK has found distinct differences in patient characteristics, available treatment options, and tumor biologic characteristics that may explain the gap.
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.